Impact of GPCR structures on drug discovery

M Congreve, C de Graaf, NA Swain, CG Tate - Cell, 2020 - cell.com
Structures of 70 unique G protein-coupled receptors (GPCRs) have been determined, with
over 370 structures in total bound to different ligands and the receptors in various …

Metal toxicity links to Alzheimer's disease and neuroinflammation

TJ Huat, J Camats-Perna, EA Newcombe… - Journal of molecular …, 2019 - Elsevier
As the median age of the population increases, the number of individuals with Alzheimer's
disease (AD) and the associated socio-economic burden are predicted to worsen. While …

Reimagining cholinergic therapy for Alzheimer's disease

E Giacobini, AC Cuello, A Fisher - Brain, 2022 - academic.oup.com
Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

Therapeutics of Alzheimer's disease: Past, present and future

R Anand, KD Gill, AA Mahdi - Neuropharmacology, 2014 - Elsevier
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …

[HTML][HTML] Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases

DA Ryskamp, S Korban, V Zhemkov… - Frontiers in …, 2019 - frontiersin.org
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in
endoplasmic reticulum (ER) membranes and changes in its function and/or expression have …

Muscarinic acetylcholine receptors: novel opportunities for drug development

AC Kruse, BK Kobilka, D Gautam, PM Sexton… - Nature reviews Drug …, 2014 - nature.com
The muscarinic acetylcholine receptors are a subfamily of G protein-coupled receptors that
regulate numerous fundamental functions of the central and peripheral nervous system. The …

Therapeutics of neurotransmitters in Alzheimer's disease

R Kandimalla, PH Reddy - Journal of Alzheimer's Disease, 2017 - content.iospress.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the
loss of memory, multiple cognitive impairments and changes in the personality and …

The cholinergic system, the adrenergic system and the neuropathology of Alzheimer's disease

RA Bekdash - International Journal of Molecular Sciences, 2021 - mdpi.com
Neurodegenerative diseases are a major public health problem worldwide with a wide
spectrum of symptoms and physiological effects. It has been long reported that the …

[HTML][HTML] Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease

K Kumar, A Kumar, RM Keegan… - Biomedicine & …, 2018 - Elsevier
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by
progressive deterioration of cognitive functions. The pathological hallmarks are extracellular …

Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease

Y Xu, J Yan, P Zhou, J Li, H Gao, Y Xia, Q Wang - Progress in neurobiology, 2012 - Elsevier
Cognitive dysfunction is one of the most typical characteristics in various neurodegenerative
diseases such as Alzheimer's disease and Parkinson's disease (advanced stage). Although …